1
|
Keaney T, O'Connor L, Krawczyk J, Abdelrahman MA, Hayat AH, Murray M, O'Dwyer M, Percy M, Langabeer S, Haslam K, Glynn B, Mullen C, Keady E, Lahiff S, Smith TJ. A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms. J Clin Pathol 2017; 70:662-668. [PMID: 28143941 DOI: 10.1136/jclinpath-2016-204205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 12/15/2016] [Indexed: 11/03/2022]
Abstract
AIMS Somatic insertions/deletions in exon 9 of the calreticulin gene have been identified in patients with essential thrombocythemia and primary myelofibrosis. Over 55 mutations have been discovered, 80% of which consist of either type 1 52-bp deletion or type 2 5-bp insertion. Other mutations (types 3-5) in conjunction with types 1 and 2 account for >87% of identified mutations. The aim of this study was development of a rapid PCR-based assay using LightCycler Hybridisation Probes for the detection of type 1-5 CALR mutations. METHOD A real-time PCR assay using a novel HybProbe set was developed for use on the LightCycler 480 Instrument II. The acceptor probe was labelled with LC640 and Faststart DNA Master HybProbe kit was used for PCR reactions. RESULTS Assay limit of detection was determined to be seven target copies with a probability of 95%. The specificity of the assay was determined by using synthetic constructs of CALR wild-type and CALR mutation types 1-5 with no non-specific detection observed. Samples from 21 patients with essential thrombocythemia (ET) and 12 patients with primary myelofibrosis (PMF), together with 29 control samples from patients diagnosed with various conditions, were screened using the assay. Of these, 24 were found to have mutations in CALR exon 9, with the assay detecting 8 type 1 mutations, 12 type 2 mutations, 2 type 24 mutations, 1 type 20 mutation and 1 31-bp deletion. CONCLUSIONS The novel assay described has potential for application as a rapid, sensitive, high-throughput screening method in the clinical diagnostics setting.
Collapse
Affiliation(s)
- Thomas Keaney
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland
| | - Louise O'Connor
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland.,Molecular Diagnostic Research Group, School of Natural Sciences, National University of Ireland, Galway, Ireland
| | - Janusz Krawczyk
- Department of Haematology, National University of Ireland, Galway, Ireland.,Galway University Hospital, Galway, Ireland
| | - Moutaz A Abdelrahman
- Department of Haematology, National University of Ireland, Galway, Ireland.,Galway University Hospital, Galway, Ireland
| | - Amjad H Hayat
- Department of Haematology, National University of Ireland, Galway, Ireland.,Galway University Hospital, Galway, Ireland
| | - Margaret Murray
- Department of Haematology, National University of Ireland, Galway, Ireland.,Galway University Hospital, Galway, Ireland
| | - Michael O'Dwyer
- Department of Haematology, National University of Ireland, Galway, Ireland.,Galway University Hospital, Galway, Ireland
| | - Melanie Percy
- Department of Haematology, Belfast City Hospital, Belfast, UK
| | | | - Karl Haslam
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Barry Glynn
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland
| | - Ciara Mullen
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland
| | - Evelyn Keady
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland
| | - Sinéad Lahiff
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland
| | - Terry J Smith
- Research and Development Division, Advanced Molecular Systems, Galway, Ireland.,Molecular Diagnostic Research Group, School of Natural Sciences, National University of Ireland, Galway, Ireland
| |
Collapse
|
2
|
Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T, Chuncharunee S, Rerkamnuaychoke B. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev 2016; 17:4647-4653. [PMID: 27892678 PMCID: PMC5454611 DOI: 10.22034/apjcp.2016.17.10.4647] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Background: The discovery of somatic acquired mutations of JAK2 (V617F) in Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has not only improved rational disease classification and prognostication but also brings new understanding insight into the pathogenesis of diseases. Dosage effects of the JAK2 (V617F) allelic burden in Ph-negative MPNs may partially influence clinical presentation, disease progression, and treatment outcome. Material and Methods: Pyrosequencing was performed to detect JAK2 (V617F) and MPL (W515K/L) and capillary electrophoresis to identify CALR exon 9 mutations in 100 samples of Ph-negative MPNs (38.0 PV, 55 ET, 4 PMF, and 3 MPN-U). Results: The results showed somatic mutations of JAK2 (V617F) in 94.7% of PV, 74.5% of ET, 25.0% of PMF, and all MPN-U. A high proportion of JAK2 (V617F) mutant allele burden (mutational load > 50.0%) was predominantly observed in PV when compared with ET. Although a high level of JAK2 (V617F) allele burden was strongly associated with high WBC counts in both PV and ET, several hematological parameters (hemoglobin, hematocrit, and platelet count) were independent of JAK2 (V617F) mutational load. MPL (W515K/L) mutations could not be detected whereas CALR exon 9 mutations were identified in 35.7% of patients with JAK2 negative ET and 33.3% with JAK2 negative PMF. Conclusions: The JAK2 (V617F) allele burden may be involved in progression of MPNs. Furthermore, a high level of JAK2 (V617F) mutant allele appears strongly associated with leukocytosis in both PV and ET.
Collapse
Affiliation(s)
- Roongrudee Singdong
- Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Haslam K, Conneally E, Flynn CM, Cahill MR, Gilligan O, O'Shea D, Langabeer SE. CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther 2016; 9:112-5. [PMID: 27352261 DOI: 10.1016/j.hemonc.2016.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 05/31/2016] [Indexed: 11/17/2022] Open
Abstract
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like deletion mutations were the most common (n=40) followed by Type 2 and Type 2-like insertion mutations (n=17). The CALR mutation profile in Irish ET and PMF patients appears similar to that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will improve clinical management.
Collapse
Affiliation(s)
- Karl Haslam
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | | | | | - Mary R Cahill
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | - Oonagh Gilligan
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | - Derville O'Shea
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | | |
Collapse
|